- Home
- CANF vs NML Comparison
CANF vs NML Comparison
Compare CANF & NML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | NML |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 497.5M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | NML |
|---|---|---|
| Price | $3.43 | $10.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | ★ 582.2K | 168.2K |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | $290,391.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $7.10 |
| 52 Week High | $10.40 | $10.44 |
Technical Indicators
Market Signals| Indicator | CANF | NML |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 59.90 |
| Support Level | $0.60 | $9.93 |
| Resistance Level | $4.74 | $10.44 |
| Average True Range (ATR) | 0.66 | 0.17 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 1.56 | 37.24 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.